BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 25, 2006
 |  BioCentury  |  Strategy

Merck-Serono pipeline

Merck-Serono pipeline

Merck-Serono pipeline
Combined pipeline from Merck KGaA and Serono listed by disease class. (A) Phase III testing of a new formulation of Rebif, which is already marketed for multiple sclerosis (MS); (B) Erbitux is marketed for squamous cell carcinoma of the head and neck (SCCHN) and colorectal cancer. NA = Not available
Product Company Target Indication(s)

Read the full 320 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >